ArticleViruses2022

SARS-CoV-2 Pre-Exposure Prophylaxis with Sotrovimab and Tixagevimab/Cilgavimab in Immunocompromised Patients-A Single-Center Experience.

David Totschnig et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.